Antiphospholipid Syndrome (APS) – A Complete Patient Guide

Overview

Antiphospholipid syndrome (APS) is an autoimmune disorder in which the immune system mistakenly produces antibodies that target phospholipid‑binding proteins in the blood. These antibodies increase the tendency of blood to clot (thrombosis) and can cause pregnancy complications such as recurrent miscarriage, stillbirth, or premature birth.

Who it affects

• Both men and women, but women are more frequently diagnosed because of the pregnancy‑related manifestations.
• Typically presents in adults aged 20–50, although children and older adults can be affected.
• It can occur as a primary condition (primary APS) or secondary to another autoimmune disease, most commonly systemic lupus erythematosus (SLE).

Prevalence

• Estimated to affect 1–5 % of the general population, but exact numbers vary because many cases are asymptomatic.
• Among patients with unexplained venous or arterial thrombosis, up to 20 % test positive for antiphospholipid antibodies.
• In women with recurrent pregnancy loss (≥ 2 consecutive miscarriages), APS is present in 10–20 % of cases (Mayo Clinic, 2023).

Symptoms

APS is a “clinical syndrome,” meaning the diagnosis requires both laboratory evidence (antibodies) and characteristic symptoms. Symptoms differ based on whether clotting or pregnancy complications dominate.

Thrombotic manifestations

• Deep‑vein thrombosis (DVT): Pain, swelling, warmth, and redness in the leg; may lead to pulmonary embolism if a clot dislodges.
<
• Pulmonary embolism (PE): Sudden shortness of breath, chest pain that worsens with breathing, rapid heart rate, coughing up blood.
• Arterial thrombosis: Stroke, transient ischemic attack (TIA), or peripheral arterial occlusion causing limb pain, pallor, or coldness.
• Cardiac involvement: Valve thickening (Libman‑Sacks endocarditis), myocardial infarction without typical atherosclerosis.
• Microvascular thrombosis: Skin livedo reticularis (net‑like purplish pattern), digital ischemia, or painful fingertips (Raynaud‑like episodes).

Obstetric manifestations

• Recurrent early miscarriage (≥ 2 consecutive losses before 10 weeks).
• Late‑pregnancy loss (stillbirth or fetal death after 10 weeks).
• Pre‑eclampsia or eclampsia, especially early‑onset (< 34 weeks).
• Placental insufficiency leading to intrauterine growth restriction (IUGR) or preterm birth.

Non‑thrombotic symptoms (less common)

• Neurologic complaints without clear stroke – headaches, migraines, cognitive dysfunction ("brain fog").
• Hematologic abnormalities – thrombocytopenia, hemolytic anemia.
• Kidney involvement – renal artery thrombosis, hypertension.
• Skin lesions – ulceration, necrosis, or the “blue‑toe” syndrome.

Causes and Risk Factors

APS is triggered by an abnormal immune response. The precise cause is unknown, but several factors increase risk.

Immunologic mechanisms

• Production of antiphospholipid antibodies (aPL) – mainly lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti‑β2‑glycoprotein I (β2GPI) antibodies.
• These antibodies interfere with normal coagulation pathways, activate endothelial cells, platelets, and complement, promoting clot formation.

Risk factors

• Other autoimmune diseases: Systemic lupus erythematosus (SLE) carries the highest secondary APS risk (up to 40 %).
• Genetic predisposition: Certain HLA haplotypes (e.g., HLA‑DR4) are linked to higher aPL production.
• Infections: Chronic infections (e.g., hepatitis C, HIV) and acute viral infections can temporarily raise aPL titers.
• Medications: Some drugs (e.g., quinidine, phenytoin) have been associated with drug‑induced aPL.
• Age and gender: Women of child‑bearing age are more likely to be diagnosed because obstetric criteria are part of the definition.
• Smoking and obesity: Promote a pro‑thrombotic state and may exacerbate APS manifestations.

Diagnosis

Diagnosing APS requires a combination of clinical events and laboratory confirmation, as outlined by the 2006 Revised Sydney Criteria.

Clinical criteria (any one required)

• Vascular thrombosis – one or more arterial, venous, or small‑vessel occlusions.
• Pregnancy morbidity – as described in the “Obstetric manifestations” section.

Laboratory criteria (any one, documented on two occasions ≥ 12 weeks apart)

• Lupus anticoagulant (LA): Detected by coagulation assays (e.g., dilute Russell viper venom time).
• Anticardiolipin antibodies (aCL): IgG or IgM isotype, measured by ELISA; medium or high titer (≥ 40 GPL or MPL).
• Anti‑β2‑glycoprotein I (β2GPI) antibodies: IgG or IgM, measured by ELISA; moderate‑to‑high titer.

Additional investigations

• Imaging for thrombosis: Doppler ultrasound for DVT, CT pulmonary angiography for PE, MRI/MRA for cerebral events.
• Cardiac evaluation: Echocardiography (look for valve lesions).
• Obstetric monitoring: Serial ultrasounds, Doppler studies of uterine arteries.
• Baseline labs: Complete blood count, renal and liver function, lipid profile, and pregnancy test in women of child‑bearing age.

Treatment Options

Treatment aims to prevent clot formation, manage existing thromboses, and protect future pregnancies. Therapy is individualized based on risk stratification (high‑risk vs. low‑risk aPL profile, history of thrombosis, obstetric history).

Anticoagulation

• Long‑term warfarin: Target INR 2.0–3.0 for most patients with prior thrombosis. Some high‑risk patients (e.g., recurrent events) may need INR 3.0–4.0.
• Direct oral anticoagulants (DOACs): Rivaroxaban, apixaban, and dabigatran are *not* routinely recommended for APS, especially in triple‑positive patients, due to higher recurrence risk (NEJM, 2020).
• Low‑molecular‑weight heparin (LMWH): Preferred during pregnancy and peri‑operatively; dosing adjusted by weight.
• Acute clot treatment: Heparin bridge followed by warfarin; catheter‑directed thrombolysis may be used for life‑threatening arterial occlusions.

Antiplatelet therapy

• Low‑dose aspirin (81 mg daily) is often added for primary prophylaxis in patients with persistent aPL but no prior clot, especially in women planning pregnancy.

Immunomodulatory agents (selected cases)

• Hydroxychloroquine: Shown to reduce aPL titers and recurrent pregnancy loss; often used in APS secondary to SLE.
• Corticosteroids or IVIG: Reserved for catastrophic APS (CAPS) or severe thrombocytopenia.
• Rituximab: Emerging data for refractory cases or CAPS; off‑label use.

Obstetric management

• Pregnant patients generally receive therapeutic‑dose LMWH (e.g., enoxaparin 1 mg/kg twice daily) + low‑dose aspirin from conception.
• Close obstetric surveillance: weekly ultrasounds after 12 weeks, fetal growth monitoring, and blood pressure checks.
• Delivery planned at a center familiar with high‑risk obstetrics and anticoagulation management.

Lifestyle and adjunct measures

• Smoking cessation, regular aerobic exercise, and weight control.
• Compression stockings for patients with chronic venous insufficiency.
• Vaccinations (influenza, COVID‑19, pneumococcal) to reduce infection‑related clot triggers.

Living with Antiphospholipid Syndrome

APS is a chronic condition, but most people lead full, active lives with proper management.

Daily self‑care tips

• Medication adherence: Use a pill organizer or mobile reminders; never skip warfarin doses and keep INR checks regular.
• Know your INR target: Keep a record of recent INR values; contact your clinic if you’re consistently out of range.
• Stay hydrated: Dehydration increases blood viscosity – aim for ≥ 2 L fluid per day unless fluid‑restricted.
• Recognize early clot signs: Swelling, pain, sudden shortness of breath, or unilateral weakness should prompt immediate medical attention.
• Pregnancy planning: Consult your rheumatologist, hematologist, and obstetrician before trying to conceive.
• Travel precautions: Move legs frequently on long flights, wear compression socks, and stay hydrated.

Psychosocial support

• Join patient advocacy groups (e.g., APS Alliance, Lupus Foundation). Peer support reduces anxiety.
• Consider counseling to cope with chronic‑illness stress, especially if dealing with pregnancy loss.
• Workplace accommodations: request flexible schedules for INR monitoring or infusion appointments.

Prevention

While you cannot eliminate the underlying autoimmune process, you can reduce the likelihood of clot formation and pregnancy complications.

• Control traditional cardiovascular risk factors – blood pressure, cholesterol, diabetes, and smoking.
• Maintain a healthy BMI (18.5–24.9 kg/m²).
• Take low‑dose aspirin if prescribed, especially before conception.
• Stay up‑to‑date on vaccinations to avoid infections that may trigger antibody spikes.
• Limit estrogen‑containing contraceptives or hormone therapy unless specifically cleared by a hematologist (estrogens raise clot risk).

Complications

If APS is inadequately treated, the following serious complications can arise.

• Recurrent thrombosis: May lead to chronic venous insufficiency, post‑thrombotic syndrome, or repeated strokes.
• Catastrophic antiphospholipid syndrome (CAPS): Rapid, widespread clotting involving multiple organs; mortality ≈ 30 % despite aggressive therapy.
• Pregnancy loss: Recurrent miscarriage, stillbirth, or severe pre‑eclampsia.
• Organ damage: Renal artery thrombosis → hypertension and kidney failure; myocardial infarction without atherosclerosis.
• Neurologic sequelae: Cognitive decline, chronic headaches, or small‑vessel disease leading to dementia.

When to Seek Emergency Care

---

**Sources:** Mayo Clinic. Antiphospholipid syndrome. 2023; CDC. Antiphospholipid Antibody Syndrome. 2022; NIH National Heart, Lung, & Blood Institute. “APS Treatment Guidelines.” 2021; WHO. “Autoimmune disorders: Global burden.” 2022; NEJM. “Rivaroxaban vs Warfarin in Antiphospholipid Syndrome.” 2020; Cleveland Clinic. “Living with APS.” 2023.